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European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to various food(s)/food constituent(s) not supported by pertinent human data. The scientific 
substantiation is based on the information provided by the Member States in the consolidated list of 
Article 13 health claims and references that EFSA has received from Member States or directly from 
stakeholders. 
The references provided in relation to the claims evaluated in this opinion included studies which 
assessed the effects of food(s)/food constituent(s) other than the food(s)/food constituent(s) which are 
the subject of the claims, and/or investigated health outcomes unrelated to the claimed effects. No 
human studies which investigated the effects of the food(s)/food constituent(s) on appropriate 
measures of the claimed effects were provided. The Panel considers that no conclusions can be drawn 
from any of the references provided for the scientific substantiation of the claims evaluated in this 
opinion. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1193, EFSA-Q-2008-1249, EFSA-Q-2008-1259, 
EFSA-Q-2008-1330, EFSA-Q-2008-1446, EFSA-Q-2008-1465, EFSA-Q-2008-1483, EFSA-Q-2008-1645, EFSA-Q-
2008-2118, EFSA-Q-2008-2140, EFSA-Q-2008-2174, EFSA-Q-2008-2175, EFSA-Q-2008-2250, EFSA-Q-2008-2349, 
EFSA-Q-2008-2363, EFSA-Q-2008-2588, EFSA-Q-2008-2593, EFSA-Q-2008-2714, EFSA-Q-2008-2859, EFSA-Q-
2008-3247, EFSA-Q-2008-3859, EFSA-Q-2008-4750, EFSA-Q-2010-00454, EFSA-Q-2010-00625, EFSA-Q-2010-
00665, EFSA-Q-2010-00671, adopted on 08 April 2011. Question No EFSA-Q-2008-2273, EFSA-Q-2008-2274, EFSA-
Q-2008-2275, EFSA-Q-2008-2276, EFSA-Q-2008-2277, EFSA-Q-2008-2280, adopted on 13 May 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims for the preparatory work on 
this scientific opinion: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen.  
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On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of the food(s)/food constituent(s) and the claimed effects 
evaluated in this opinion. 
KEY WORDS 
Muscle mass, joints, bone, energy-yielding metabolism, endurance performance, endurance capacity, protein 
metabolism, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
The approach used in the evaluation of Article 13(1) health claims is explained in the general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
6
. 
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:  
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (“beneficial to human health”);  
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
For a claim, each relationship between a food/constituent and a claimed effect is assessed separately 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1. Relevance of the claimed effect to human health 
1.1. Growth or maintenance of muscle mass (ID 858, 1536, 1540, 4038, 4712) 
The claimed effects are “guard against symptoms of fatigue of skeleton muscle cells”, “increasing 
strength”, “strength and energy”, and “muscle development”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to the growth 
or maintenance of muscle mass by decreasing muscle breakdown, increasing muscle synthesis or both. 
Failure to increase muscle mass during growth and development, and the loss of muscle mass at any 
age will reduce muscle strength and power. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5 EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6 See footnote 5 
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The Panel considers that growth or maintenance of muscle mass is a beneficial physiological effect. 
1.2. Maintenance of normal joints (ID 659, 678, 696, 1513, 1627, 1855, 1981, 2126, 2514, 
4501, 4672, 4718) 
The claimed effects are “joints”, “soigne l'ostéoarthrose”, “joint health”, “articulations”, “muscles and 
joint health”, “shows anti-inflammatory properties”, “bones and joints health”, and “health of bones 
and joints, as a structural component of the cartilage”. The Panel assumes that the target population is 
the general population.  
In the context of the proposed wordings, clarifications from Member States and references provided 
for the substantiation of these claims, the Panel assumes that the claimed effects refer to the 
maintenance of normal joints. 
The Panel considers that maintenance of normal joints is a beneficial physiological effect. 
1.3. Maintenance of normal bone (ID 1860, 4501, 4672) 
The claimed effects are “bone”, “bones and joints health”, and “health of bones and joints, as a 
structural component of the cartilage”. The Panel assumes that the target population is the general 
population.  
In the context of the proposed wordings, clarifications from Member States and references provided 
for the substantiation of these claims, the Panel assumes that the claimed effects refer to the 
maintenance of normal bone. 
The Panel considers that maintenance of normal bone is a beneficial physiological effect. 
1.4. Contribution to normal energy-yielding metabolism (ID 1381, 1613) 
The claimed effects are “energy metabolism” and “muscles/energy”. The Panel assumes that the target 
population is the general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to 
energy-yielding metabolism. 
The Panel considers that contribution to normal energy-yielding metabolism is a beneficial 
physiological effect. 
1.5. Increase in endurance performance (ID 472, 543, 1403, 1538, 1539, 3127) 
The claimed effects are “endurance, enhanced carbohydrate delivery to muscle”, “endurance 
performance and increases carbohydrate availability”, “muscles/increase in performance”, “enhancing 
training volume and intensity”, “increasing exercise thresholds”, and “adaptogen, supports energy 
level, invigoration of the body, supports immune system”. The Panel assumes that the target 
population is adults performing endurance exercise. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in endurance performance. Endurance performance relates to the ability to complete certain 
tasks with higher intensity, faster, or with a higher power output when performing long-term exercise. 
The Panel considers that an increase in endurance performance is a beneficial physiological effect. 
Health claims related to various food(s)/food constituent(s) 
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1.6. Increase in endurance performance during the subsequent exercise bout after 
strenuous exercise (ID 462, 1437, 1438) 
The claimed effects are “recovery, glycogen restoration through ingested carbohydrate, muscle tissue 
building from the amino acids obtained from protein, muscle lipid reloading by consuming the right 
amount of dietary fat”, “carbohydrate and lipid metabolism”, and “carbohydrate metabolism”. The 
Panel assumes that the target population is adults performing endurance exercise. 
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in endurance performance during the subsequent exercise bout after strenuous exercise.  
Endurance performance relates to the ability to complete certain tasks with higher intensity, faster, or 
with a higher power output when performing long-term exercise. 
The Panel considers that an increase in endurance performance during the subsequent exercise bout 
after strenuous exercise is a beneficial physiological effect. 
1.7. Increase in performance during intense and repeated anaerobic exercise bouts 
(ID 1543) 
The claimed effect is “enhancing anaerobic working capacity”. The Panel assumes that the target 
population is individuals performing sports which require intense and repeated exercise bouts. 
In the context of the proposed wordings and references provided, the Panel assumes that the claimed 
effect refers to the increase in exercise performance, which in the present context refers to performing 
repeated exercise bouts with higher intensity, faster or with a higher power output. 
The Panel considers that an increase in performance during intense and repeated anaerobic exercise 
bouts is a beneficial physiological effect. 
1.8. Increase in endurance capacity (ID 1537, 1538) 
The claimed effects are “increasing work capacity”, and “enhancing training volume and intensity”. 
The Panel assumes that the target population is adults performing endurance exercise.  
In the context of the proposed wordings, the Panel assumes that the claimed effects refer to an 
increase in endurance capacity. Endurance capacity refers to the exercise time to self-reported fatigue 
when exercising at a constant workload or speed, generally at intensity <80 % maximum O2 
consumption.  
The Panel considers that an increase in endurance capacity is a beneficial physiological effect.  
1.9. Contribution to normal protein metabolism (ID 406) 
The claimed effect is “formation and activation of protein”. The Panel assumes that the target 
population is the general population.  
In the context of the proposed wordings and clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to protein metabolism.  
The Panel considers that the contribution to normal protein metabolism is a beneficial physiological 
effect. 
Health claims related to various food(s)/food constituent(s) 
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2. Scientific substantiation of the claimed effect 
2.1. Growth or maintenance of muscle mass (ID 858, 1536, 1540, 4038, 4712)  
The references provided in relation to these claims included textbooks, narrative reviews or 
monographs which did not provide any original data for the scientific substantiation of the claims and 
human intervention studies on the effects of food constituents other than the specific combination of 
food constituents which is the subject of some claims (ID 1536, 1540, 4712). The Panel considers that 
no conclusions can be drawn from these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s)/combination of 
food constituents on the growth or maintenance of muscle mass were provided in relation to any of 
the claims evaluated in this section. 
Two references addressed the effects of the food(s)/food constituent(s) on muscle contractility, on the 
generation of free radicals and on lipid peroxidation in skeletal muscle in vitro using muscle biopsies 
and electrical stimulation. The Panel considers that evidence provided in in vitro studies is not 
sufficient to predict the occurrence of an effect of the consumption of the food(s)/food constituent(s) 
on the growth or maintenance of muscle mass in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s)/combination of food constituents, which are the 
subject of the claims evaluated in this section, and growth or maintenance of muscle mass.  
2.2. Maintenance of normal joints (ID 659, 678, 696, 1513, 1627, 1855, 1981, 2126, 2514, 
4501, 4672, 4718)  
The references provided in relation to these claims included textbooks, narrative reviews and 
monographs which did not provide any original data for the scientific substantiation of the claims. 
The Panel considers that no conclusions can be drawn from these references for the scientific 
substantiation of the claims. 
Some human intervention studies, which investigated the effects of the food(s)/food constituent(s) on 
the treatment of osteoarthrosis or (osteo)arthritis of different origin (rheumatoid arthritis, psoriatic 
arthritis, arthritis of infectious origin), were submitted. The Panel considers that the evidence 
provided does not establish that patients with osteoarthrosis or (osteo)arthritis of different origin are 
representative of the general population with regard to the status of joint tissues, or that results 
obtained in studies on subjects with osteoarthrosis or (osteo)arthritis of different origin and related to 
the treatment of symptoms of these diseases (e.g. erosion of articular cartilage, reduced mobility of 
joints) can be extrapolated to the maintenance of normal joints in the general population. Thus, for 
claims supported only by references to human studies on patients with osteoarthrosis or 
(osteo)arthritis of different origin, the Panel considers that a cause and effect relationship has not been 
established between the consumption of the food(s)/food constituent(s) and the claimed effect in the 
general population. 
No human studies which investigated the effects of the food(s)/food constituent(s) on the maintenance 
of normal joints were provided in relation to any of the claims evaluated in this section. 
A number of in vitro studies were provided which addressed the effects of different food(s)/food 
constituent(s) on human chondrocytes/cartilage explants, chondrocyte cell lines and expression of cell 
surface molecules. Studies on the relationship between the intake of the food(s)/food constituent(s) 
and the claimed effect in animal models of experimentally-induced arthritis were also provided.  
Health claims related to various food(s)/food constituent(s) 
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The Panel considers that evidence provided in in vitro studies is not sufficient to predict the 
occurrence of an effect of the consumption of the food(s)/food constituent(s) on the maintenance of 
normal joints in vivo in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s), which are the subject of the claims evaluated in this 
section, and maintenance of normal joints. 
2.3. Maintenance of normal bone (ID 1860, 4501, 4672) 
The references provided in relation to these claims were textbooks, narrative reviews and monographs 
which did not provide any original data for the scientific substantiation of the claims or reported on 
health outcomes (e.g. treatment of osteoarthritis) unrelated to the claimed effect. The Panel considers 
that no conclusions can be drawn from these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on the maintenance 
of normal bone were provided in relation to any of the claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this 
section and maintenance of normal bone. 
2.4. Contribution to normal energy-yielding metabolism (ID 1381, 1613) 
The references provided in relation to these claims were monographs and narrative reviews which did 
not provide any original data for the scientific substantiation of the claims or addressed health 
outcomes (e.g. daily activity in a murine model of chronic fatigue syndrome, treatment of 
fibromyalgia) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn 
from these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s) on contribution to 
normal energy-yielding metabolism were provided in relation to any of the claims evaluated in this 
section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s), which are the subject of the claims evaluated in this 
section, and contribution to normal energy-yielding metabolism.  
2.5. Increase in endurance performance (ID 472, 543, 1403, 1538, 1539, 3127) 
The references provided in relation to these claims were monographs and narrative reviews which did 
not provide any original data for the scientific substantiation of the claims or addressed health 
outcomes (e.g. antioxidant activity, immune parameters, blood flow) unrelated to the claimed effect, 
studies which assessed the effects of food constituents other than the food constituent(s) or the 
specific combinations which are the subject of the claims on measures of endurance performance, 
and/or investigated health outcomes (e.g. rate of exogenous carbohydrate oxidation, muscle strength) 
other than endurance performance. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s)/combination of 
food constituents on measures of performance during endurance exercise were provided in relation to 
any of the claims evaluated in this section. 
Health claims related to various food(s)/food constituent(s) 
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The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s)/combination of food constituents which are the subject 
of the claims evaluated in this section and increase in endurance performance. 
2.6. Increase in endurance performance during the subsequent exercise bout after 
strenuous exercise (ID 462, 1437, 1438) 
The references provided in relation to these claims included narrative reviews or studies which 
addressed the effects of food(s)/food constituent(s) other than the food constituent(s) or the specific 
combination of food constituents which are the subject of the claims, and/or investigated health 
outcomes (e.g. gastric emptying rate, blood glucose concentration, serum insulin concentration) 
unrelated to the claimed effect. The references also included one study on the specific combination of 
the food constituents which is the subject of the claim on health outcomes (e.g. muscle glycogen 
stores) other than endurance performance. The Panel considers that no conclusions can be drawn from 
these references for the scientific substantiation of the claims. 
No human studies which investigated the effects of the food(s)/food constituent(s)/combination of 
food constituents on an increase in endurance performance during the subsequent exercise bout after 
strenuous exercise were provided in relation to any of the claims evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food(s)/food constituent(s)/combination of food constituents which are the subject 
of the claims evaluated in this section and increase in endurance performance during the subsequent 
exercise bout after strenuous exercise. 
2.7. Increase in performance during intense and repeated anaerobic exercise bouts 
(ID 1543) 
The references provided for the scientific substantiation of this claim included a number of human 
intervention studies which investigated the effect of food constituents other than the specific 
combination of food constituents which is the subject of the claim, and/or assessed health outcomes 
(e.g. muscle strength, endurance capacity) unrelated to the claimed effect. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim. 
Among the references provided was a human intervention study in which participants were 
randomised to receive the specific combination of food constituents which is the subject of the claim 
or a “placebo” matched with the intervention, except for one constituent (Kreider et al., 1998). The 
Panel notes that the placebo used in this study does not allow conclusions to be drawn on an effect of 
the specific combination of food constituents which is the subject of the claim. The Panel considers 
that no conclusions can be drawn from this reference for the scientific substantiation of the claim. 
No human studies which investigated the effects of the specific combination of food constituents on 
an increase in performance during intense and repeated anaerobic exercise bouts were provided in 
relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the combination of food constituents which is the subject of the claim evaluated in 
this section and increase in performance during intense and repeated anaerobic exercise bouts. 
2.8. Increase in endurance capacity (ID 1537, 1538) 
The references provided for the scientific substantiation of this claim included a number of human 
intervention studies which investigated the effect of food constituent(s) other than the specific 
Health claims related to various food(s)/food constituent(s) 
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combination of food constituents which is the subject of the claims. The Panel considers that no 
conclusions can be drawn from these references for the scientific substantiation of the claim. 
No human studies which investigated the effects of the specific combination of food constituents on 
an increase in endurance capacity were provided in relation to any of the claims evaluated in this 
section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the combination of food constituents which is the subject of the claims evaluated in 
this section and increase in endurance capacity. 
2.9. Contribution to normal protein metabolism (ID 406) 
The reference provided in relation to this claim was a pharmacy leaflet which did not provide any 
original data for the scientific substantiation of the claim. The Panel considers that no conclusions can 
be drawn from this reference for the scientific substantiation of the claim. 
No human studies which investigated the effects of the food on contribution to normal protein 
metabolism were provided in relation to the claim evaluated in this section. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of the food which is the subject of the claim evaluated in this section and contribution to 
normal protein metabolism.  
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 A cause and effect relationship has not been established between the consumption of the 
food(s)/food constituent(s) and the claimed effects evaluated in this opinion. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1193, 
EFSA-Q-2008-1249, EFSA-Q-2008-1259, EFSA-Q-2008-1330, EFSA-Q-2008-1446, EFSA-Q-2008-
1465, EFSA-Q-2008-1483, EFSA-Q-2008-1645, EFSA-Q-2008-2118, EFSA-Q-2008-2140, EFSA-Q-
2008-2174, EFSA-Q-2008-2175, EFSA-Q-2008-2250, EFSA-Q-2008-2273, EFSA-Q-2008-2274, 
EFSA-Q-2008-2275, EFSA-Q-2008-2276, EFSA-Q-2008-2277, EFSA-Q-2008-2280, EFSA-Q-2008-
2349, EFSA-Q-2008-2363, EFSA-Q-2008-2588, EFSA-Q-2008-2593, EFSA-Q-2008-2714, EFSA-Q-
2008-2859, EFSA-Q-2008-3247, EFSA-Q-2008-3859, EFSA-Q-2008-4750, EFSA-Q-2010-00454, 
EFSA-Q-2010-00625, EFSA-Q-2010-00665, EFSA-Q-2010-00671). The scientific substantiation is 
based on the information provided by the Member States in the consolidated list of Article 13 health 
claims and references that EFSA has received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES  
Kreider RB, Ferreira M, Wilson M, Grindstaff P, Plisk S, Reinardy J, Cantler E and Almada AL, 
1998. Effects of creatine supplementation on body composition, strength, and sprint performance. 
Medicine and Science in Sports and Exercise, 30, 73-82. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
7
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health". 
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be: 
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3). 
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
8
  
Foods are commonly involved in many different functions
9
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent. 
                                                     
7 OJ L12, 18/01/2007 
8 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
9 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect. 
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
Health claims related to various food(s)/food constituent(s) 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects: 
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent. 
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
Health claims related to various food(s)/food constituent(s) 
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claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to various food(s)/food constituent(s) that are not supported 
by pertinent human data, including conditions of use from similar claims, as proposed in the 
Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
406 Gemüse / Rote Beete / Kalium 
Clarification provided 
beetroot as vegatable: potassium 
content 
Aktivierung / Aufbau von 
Eiweiß / Kalium 
Clarification provided 
Formation and activation of 
protein 
[In german : ] Kalium ist an 
der Aktivierung einiger 




potassium is involved in 
activation processes of several 
enzymes as well as in 
formation of protein produced 
naturally in the body 
Conditions of use 
- Es werden nur die Nährstoffe beworben, die lt. Nährwertkennzeichnungs-verordnung 
(Anlage 1) mindestens 15 Prozent der empfohlenen Tagesdosis in 100 g oder 100 ml 
enthalten. 
ID Food or Food constituent Health Relationship Proposed wording 
462 Carbohydrate, protein and lipid 
combination 
Clarification provided 
A combination food for sports 
people containing amounts of 
fats, protein and carbohydrate 
(see CoU) that replaces deletion 
of these nutrients after exercise; 
claims made for constituent 






Muscle tissue building 
from the amino acids 
obtained from protein 
Muscle lipid reloading by 
consuming the right 
amount of dietary fat 
Helps your body rapidly 
rebuild so that you can 
perform at your peak during 
your next workout. 
Rebuild muscle glycogen. 
Repair muscle protein. 
Restore muscle lipid. 
Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Metabolisable 
carbohydrates: 60 - 70% of total energy. High quality protein: 12 - 15% of total energy. 
Lipid: = 30% of total energy. 
ID Food or Food constituent Health Relationship Proposed wording 
472 
 
Glucose and fructose. Endurance Enhanced 




carbohydrate delivery to 
The ratio of 2:1 of glucose and 
fructose sources help deliver 
more energy to muscles. 
Delivers even longer lasting 
energy. 
Faster energy delivery 
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muscle. 
Endurance during sport and 
exercise. 




endurance exercise.  
Increased ingested fluid 
availability during 
endurance exercise. 
[as measured by rate of 
deuterium oxide 
accumulation in plasma] 
Co-ingestion of glucose 




useable energy/is burned 
for energy at higher rates 
during endurance exercise 




during endurance exercise 
by 20-55% compared to 
glucose sources alone. 
Delivers 20-55% more 
energy to muscles than 
glucose alone. 
Improves endurance 
performance [by 8%] 
compared to glucose 
sources alone. Delivers 8% 
longer lasting energy than 
glucose alone. 
compared with glucose. 
Delivers more sustained 
energy to muscles. 
Enahnced carbohydrate 
delivery, availability and 
utilisation. 
Conditions of use 
- Gesunde normalgewichtige Erwachsene, 50 (bis zu 100) Gramm (g), alle 60 Min.; nach 5-
10 Min. im Blut nachweisbar. Anmerkung Höchstmenge: Während körperlicher Leistung; 
an Energieverbrauch angepasst; Dextrose kann und sollte nicht als Mahlzeitersatz gesehen 
werden. Dextrose ist ein Helfer in bestimmten Situationen. 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Carbohydrates: 
= 65% of total energy (for foods). Carbohydrates: = 75% of total energy (for beverages). 
Carbohydrate ratio of glucose to fructose of 2:1. 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Carbohydrates: 
≥ 65% of total energy (for foods) and ≥ 75% (for beverages). Carbohydrate ratio of glucose 
to fructose of 2:1. 
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Comments from Member States 
Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Product must 
contain glucose and fructose sources (e.g. glucose to include free glucose, dextrose or 
maltodextrins; sources of fructose to include free fructose or sucrose). Pattern of use: product 
consumption to ensure glucose and fructose sources are co-ingested at rates of ≥ 60 and ≥ 30 
grams, respectively, per hour during endurance exercise. 
ID Food or Food constituent Health Relationship Proposed wording 
543 Caffeine and carbohydrate. 
Clarification provided 
Caffeine and carbohydrate in 
sport nutrition products: Product 
consumption to ensure a 
caffeine intake of ≥ 100 mg or ≥ 
0.9 mg/kg body mass co-
ingested with a metabolisable 
carbohydrate (e.g. glucose, 
glucose polymers, sucrose) 
intake of ≥ 30 g or ≥0.4 g/kg 
body mass per hour during 
endurance exercise. 
Endurance performance 
and increases carbohydrate 
availability. 
Helps increase carbohydrate 
availability during endurance 
exercise. 
Combination of caffeine and 
carbohydrate improves 
endurance performance. 
Conditions of use 
- Aus Teeblättern, mindestens 37,5 mg Koffein pro empfohlener Getränkemenge. 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Carbohydrate 
intake of up to ~ 1 g/min and caffeine intake of 1-5 mg/kg body mass. Beverages must 
comply with the labelling requirements laid down by Directive 2002/67/EC. 
Comments from Member States 
Claim to be only used for Foods for sportpeople under the Directive 2009/39/EC. 
ID Food or Food constituent Health Relationship Proposed wording 
659 Collagen. Joints. 
Clarification provided 
Joints; joints health and 
function, joints 
mobility/flexibility. 
Collagen can/could contribute 
to the maintenance of the 
healthy function of joints. 
Conditions of use 
- Minimum 20 microgram/day (II-type collagen). 
Comments from Member States 
EFSA accepted similar relationship, under HR_ID 1513 without comment. 
ID Food or Food constituent Health Relationship Proposed wording 
678 Glucosamine. Soigne l'ostéoarthrose. Bon pour les articulations. 
A utiliser pour maintenir les 
articulations souples. 
Efficace dans les problèmes 
d'inflammation et de mobilité 
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des articulations. 
Soulage les douleurs 
inflammatoires. 
Conditions of use 
- Exosquelette de crustacés 1500mg/jour. 
- Cartillage de requin 1200mg/jour. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
696 Evening Primrose Oil (EPO), 
Oenothera spp. and Fish Oil 
(FO) providing long chain 
omega 6 and omega 3 fatty 
acids [gamma-linolenic acid 




Helps maintain joint mobility. 
 
Conditions of use 
- Ref 7 - 240 mg eicosapentaenoic acid from Fish Oil and 450 mg gamma-linolenic acid from 
Evening Primrose Oil per day. (Note: This is 6 g of a mixture of 80% evening primrose oil 
and 20% fish oil by weight). 
ID Food or Food constituent Health Relationship Proposed wording 
858 Bioaktive Oligosaccharide, wie 
z. B. glykosylierte 
Phenylethanoide. 
Clarification provided 











against symptoms of 
fatigue of skeleton muscle 
cells. 
[In german: ] Bioaktive 
Oligosaccharide zur 
natürlichen / aktiven 




optimise mucular strength. 
Conditions of use 
- None provided 
ID Food or Food constituent Health Relationship Proposed wording 
1381 Brewer`s Yeast. Energy metabolism. 1. Activates metabolism and 
energy conversion process in 
the body, promotes effective 
assimilation of nutrients. 
2. Vitamins and micronutrients 
are highly essential for normal 
body functioning. 
Conditions of use 
- 2- 4g. 
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No clarification provided by Member States 


















can delay tiring of muscles in 
endurance sports 
Conditions of use 
- ab 600 mg/l Hydrogen-carbonat (siehe EG-Mineralwasser-Richtlinie) 
ID Food or Food constituent Health Relationship Proposed wording 
1437 Amylopectin Carbohydrate metabolism Amylopectin facilitates the 
replenishment of glycogen 
stores in skeletal muscle. 
Conditions of use 
- A serving must contain approximately 75 grams. 
ID Food or Food constituent Health Relationship Proposed wording 
1438 Amylopectin and L-carnitine Carbohydrate and lipid 
metabolism 
Amylopectin plus L-carnitine 
facilitate the replenishment of 
glycogen stores in skeletal 
muscle, and the switching 
from carbohydrate oxidation to 
fat oxidation. 
Conditions of use 
- A serving must contain approximately 75 grams of amylopectin and 1 gram of L-carnitine. 
ID Food or Food constituent Health Relationship Proposed wording 
1513 Collagen hydrolysate. Joint health. Contributes to the functioning 
of cartilage building cells. 
Supports the (natural) 
regeneration of joint cartilage. 
Stimulates the build-up of 
joint cartilage. 
Contributes to improved joint 
functioning and joint mobility. 
Contributes to joint comfort. 
Provides the building blocks 
(peptides) for the biosynthesis 
of cartilage. 
Provides strength, flexibility 
and support to skin connective 
tissues, ligaments, tendons, 
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bones and other parts of the 
body. 
Conditions of use 
- 10 g täglich (Typ I Collagen mit durchschn. Molekulargewicht bis zu 3.500 Dalton). 
- 10 g per day (Type I collagen with an average Molecular Weight of up to 3.500 Dalton). 
- 10 Gramm (g)/Tag, mindestens 3 Monate. 
- 1500 mg Biocell Kollagen Typ II. 
- Längerfristige tägliche Zufuhr von mindestens ca. 5 g Gelatine. 
- 10 g/Tag. 10g täglich (Typ I Collagen mit durchschn.Molekulargewicht bis zu 3.500 
Dalton) 
- 10 g pro Tag 
- 10 g/day 
- Minimum 20 microgram/day (II-type collagen). 
- 10g per day (Type I collagen with an average Molecular Weight of up to 3.500 Dalton). 
10gr/day with a recommended continuous use of at least 3 months 
- 10 gr/day with a recommended continuous use of at least 3 months. 
- 10 gr./Tag mit einer empfohlenen Dauer von mindestens 3 Monaten. 
- 5 to 10 g daily. 
- Täglich mindestens ca. 5 g Gelatine––(Gesamte Bevölkerung). 
- Producer’s recommendation: daily dose of at least 8 mg. RDD was not specified. 
Administration: Regularly 1 cube a day in the morning before meal for at least 2 to 3 
months, repeat twice a year. 
ID Food or Food constituent Health Relationship Proposed wording 
1536 EAS Phosphagen Elite Increasing Strength EAS Phosphagen Elite is 
clinically shown to boost 
muscular strength 
EAS Phosphagen Elite is 
clinically shown to increase 
strength by up to 15% 
EAS Phosphagen Elite is 
designed to boost overall 
muscular strength 
Boost muscular strength 
Conditions of use 
- The product must contain at least 5 gram creatine monohydrate, 1 gram taurine and 33 
grams dextrose and 1.6 grams beta-alanine per serving. Claim to be used for foods for 
active individuals.  
ID Food or Food constituent Health Relationship Proposed wording 
1537 EAS Phosphagen Elite Increasing Work Capacity EAS Phosphagen Elite is 
clinically shown to increase 
anaerobic threshold  
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EAS Phosphagen Elite is 
clinically shown to increase 
physical 
working capacity at fatigue 
threshold 
Conditions of use 
- The product must contain at least 5 gram creatine monohydrate, 1gram taurine and 33 
grams dextrose and 1.6 grams beta-alanine per serving. Claim to be used for foods for 
active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1538 EAS Phosphagen Elite Enhancing Training 
Volume & Intensity 
EAS Phosphagen Elite is 
designed to provide a higher 
quality workout, 
and the addition of beta alanine 
appears to enhance average 
training 
volume more so than creatine 
alone 
EAS Phosphagen Elite is 
clinically shown to result in 
greater training volume 
threshold 
Conditions of use 
- The product must contain at least 5 gram creatine monohydrate, 1 gram taurine and 33 
grams dextrose and 1.6 grams beta-alanine per serving. Claim to be used for foods for 
active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1539 EAS Phosphagen Elite Increasing Exercise 
Thresholds 
Amp up your workout with EAS 
Phosphagen 
Elite, clinically shown to 
improve ventilatory and lactate 
thresholds for greater 
cardiorespiratory endurance in 
intense workouts (training) 
EAS Phosphagen Elite is 
clinically shown to improve 
ventilatory and lactate 
thresholds 
Conditions of use 
- The product must contain at least 5 gram creatine monohydrate, 1gram taurine and 33 
grams dextrose and 1.6 grams beta-alanine per serving. Claim to be used for foods for 
active individuals 
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ID Food or Food constituent Health Relationship Proposed wording 
1540 EAS Phosphagen HP Increasing Strength EAS Phosphagen HP is 
clinically shown to increase 
strength 
EAS Phosphagen HP is 
clinically shown to boost 
muscular strength 
EAS Phosphagen HP is 
designed to boost overall 
muscular strength 
Conditions of use 
- The product must contain at least 5 gram creatine monohydrate, 1 gram taurine and 33 
grams dextrose per serving. Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1543 EAS Phosphagen HP Enhancing Anaerobic 
Working Capacity 
EAS Phosphagen HP can help 
improve total anaerobic work 
performed EAS Phosphagen HP 
is clinically tested to help 
improve anaerobic work 
capacity 
EAS Phosphagen HP can help 
improve total anaerobic work 
performed 
Conditions of use 
- the product must contain at least 5 gram creatine monohydrate, 1gram taurine and 33 grams 
dextrose per serving  
- Claim to be used for foods for active individuals 
ID Food or Food constituent Health Relationship Proposed wording 
1613 Malic acid Muscles/energy Malic acid is needed for proper 
functioning of the energy cycle 
Conditions of use 
- 600mg/daily minimum is suggested. Safety during pregnancy/lactation has not been 
established. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1627 Omega-3 fatty acids 
(Hi-EPA) with Glucosamine. 
Joint health. Omega-3 fatty acids (Hi-EPA) 
with Glucosamine help to 
maintain joint health. 
Conditions of use 
- 200-500mg EPA, 50-250mg DHA, 1-1.5g Glucosamine per day. 
-  
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ID Food or Food constituent Health Relationship Proposed wording 
1855 Shark cartilage + greenshell 
mussel. 
Clarification provided 
Shark cartilage + greenshell 
mussel. Daily dose (2-6 
capsules) contains 220-660 mg 
of greenshell mussel powder 
and 200-600 mg of shark 
cartilage powder and 200-600 
mg och shark cartilage extract 
(contains 240-720 mg 
glycosaminoglycans, of which 
190-570 mg is chondroitin 
sulphate). 
Joints. Supports joint functioning. 
For joint health. 
Supports joint well-being 
Conditions of use 
- Food supplement with 220-260 mg of greenshell mussel powder and 200-600 mg of shark 
cartilage (contains 240-720 mg glycosamineglycans, of which 190-570 mg is chondroitin 
sulphate) in the daily dose. 
Comments from Member States 
Addtion to conditions of use. New succestion to the claims: Contains chondroprotective agents; 
Enhances joint fluid production. 
ID Food or Food constituent Health Relationship Proposed wording 
1860 Soy + magnesium + calcium + 
zinc + manganese + copper + 
vitamin B6 + vitamin D + 
vitamin K 
Bone Strong bones. 
The best for your bones. 
Good ageing. 
The soy flavones and mineral 
substances, calcium, 
magnesium, zinc, manganese 
and copper, together with 
vitamins B6, D and K protect 
the bones. 
Name or symbol included in 
the claim: Osteobalans® 
Conditions of use 
- Food supplement with 40 mg of soy flavones, 100 mg of magnesium, 200 mg of calcium, 
15 mg of zinc, 2.5 mg of manganese, 2.0 mg of copper, 2.2 mg of vitamin B6, 5 µg of 
vitamin D and 70 µg of vitamin K in the daily dose. The state of the microbe population in 
the gut affects the usefulness of the soy isoflavones in the body. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
1981 Cartilage de requin. Articulations. Souplesse et mobilité des 
articulations - Bien-être des 
articulations. 
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Conditions of use 
- Hydrolysat de cartilage de requin. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
2126 Ribes nigrum  
(Common Name: Blackcurrant). 
Muscles and joint health. Contributes to the proper 
functioning of muscles and 
joints/for supple joints. 
Conditions of use 
- Blätter / Äquivalent von getrockneten Blättern als Aufguss (20-50 g/ l). 
- Liście / równowartość 20-50 g/litr suchych liści jako napar. 
- Leaf / The equivalent of dried leaf as an infusion (20-50 g/litre). 
- Traditional use of the leaf / 2-4 g of leaves as an infusion one cup several times daily / 
Equivalent quantity in extract. 
- Leaf / 250-500 ml daily of infusion (20-50 g/litre) / 10 ml daily of fluid extract (1:1) / 
equivalent preparations. 
- Traditional use of leaf / 2-4 g cut leaves to infusing : drink one mug several times per day or 
an equivalent extract to these 2-4 g of leaves. 
ID Food or Food constituent Health Relationship Proposed wording 
2514 Ananas tige 
“criteria”: 6 
Clarification provided 











inflammatory reaction in joints 
and muscles/Helps maintain 
the flexibility and mobility of 
the joints 
Conditions of use 
- Tige 200-2000mg bromelaine 
ID Food or Food constituent Health Relationship Proposed wording 
3127 Cordyceps sinensis  Adaptogen, supports 
energy level, Invigoration 
of the body,supports 
immunesystem 
Helps to strengthen the body 
Supports immune system 
Invigorates the body 
Supports energetic alertness 
Supports the immunesystem 
by delivering antioxidants 
Increases performance and 
endurance of a heavy exercise 
or sportsactivity  
Conditions of use 
- 3 gram dried powder or equivalent extracts 
Health claims related to various food(s)/food constituent(s) 
not supported by pertinent human data (Part II)   
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ID Food or Food constituent Health Relationship Proposed wording 
4038 Emblica officinalis FRUIT 
RIND 
Strength & energy Gives strength and energy. 
Helps build muscle. 
Conditions of use 
- Powder 3-0.2 g/day; aqueous extra 1.5-0.1 g/day. All over 2 years old: 2-4 years ¼ adult 
dose, 4-10 years half adult dose 
ID Food or Food constituent Health Relationship Proposed wording 
4501 Vaccinium vitis idaea, herba Bones and Joins Health Supports the health of bones 
and joins 
Conditions of use 
- Capsules, 270 mg./day in combination with other herbs 
ID Food or Food constituent Health Relationship Proposed wording 
4672 Glucosamine sulphate Health of bones and joints, 
as a structural component 
of the cartilage 
Helpful for joints mobility, 
Helpful for structural and 
functional maintaining, 
Building of joints surface, 
ligaments, bones, blood vessel 
and skin, Contributes to 
preserve the structure and the 
elasticity grade of the 
cartilage. 
Conditions of use 
- 1000 - 1500 mg/day 
ID Food or Food constituent Health Relationship Proposed wording 
4712 Fructose, Glucose, 
Maltodextrine, Milk protein 
concentrate, 5.Soy protein 
concentrate, Creatine, Vitamin 
C, Magnezium Oxide, Zinc 
Oxide,Alimentary flavors 
Muscular Development energizer and proteic food 
supplement / recomended for 
fast increase of energy, 
strenght and muscular 
development / recovery 
musular energy after physical 
and mental effort 
Conditions of use 
- 1-2 servings of 105 g daily / Not for diabetics. 
ID Food or Food constituent Health Relationship Proposed wording 
4718 Glucosamin 500 mg, 
chondroitin 440 mg, vit. PP 6 
mg, Sodium selenit 4,8 mg.cps 
Bones and Joints Health Supports the normal synthesis 
of the conjunctive tissue of 
joints. 
Conditions of use 
- 3 capsules/day - 2838 mg. food combination /day, min. 90 days 
 
